Key result
Study examines contemporary use of guideline-recommended risk reduction strategies in patients with diabetes and ASCVD.
Why the study?
Prior analyses showed suboptimal secondary prevention in patients with ASCVD and diabetes, but lacked data on newer lipid- and glucose-lowering therapies.
Cohort
Answers are grounded in this paper and cite their sources.
Captured external expert commentary on this paper, strongest first. Original sources are linked where available.
“The effectiveness of these therapies is not in question, and yet their use in routine clinical care is astonishingly low. In the U.S., among patients with type 2 diabetes and ASCVD, only 2.7% of patients are on all three of these groups of therapies and over one-third are on none.”
“This study points to gaps in care that we must address urgently to provide the best care for these patients who at high risk for morbidity and mortality. Barriers to 100 percent utilization of these therapies are present at the patient, clinician and system levels. Patients, providers, industry, regulators, professional societies, and payers all have a role to play in translating evidence to practice.”
This study examines the contemporary utilization of evidence-based cardiovascular risk reduction therapies, including newer lipid and glucose-lowering agents, in US patients with diabetes and ASCVD.
Patients with atherosclerotic cardiovascular disease (ASCVD) and concomitant diabetes are at particularly high risk for new and recurrent ischemic events and heart failure and therefore derive greater absolute benefit from secondary prevention therapies than patients without concomitant diabetes.1 Prior analyses reported suboptimal use of evidence-based therapies in this vulnerable group1, 2 but did not include data on newer lipid and glucose-lowering therapies. Given the emergence of non-statin LDL lowering agents and glucose-lowering medications with cardiovascular benefits, the number of evidence-based therapies for secondary prevention has expanded. Thus, we examined contemporary use of medications to reduce cardiovascular risk in a large cohort of US patients with diabetes and ASCVD.
No takes yet. Share an insight, caveat, or question.
Arnold et al. (2019) conducted a cohort in Diabetes and Atherosclerotic Cardiovascular Disease. Guideline-recommended risk reduction strategies was evaluated on Contemporary use of medications to reduce cardiovascular risk.
Synapse has enriched 10 related papers. Consider them for comparative context: